QTS Declares Series B Convertible Preferred Stock Dividend
- 48
PR Newswire
OVERLAND PARK, Kan., Aug. 10, 2018
OVERLAND PARK, Kan., Aug. 10, 2018 /PRNewswire/ -- QTS Realty Trust, Inc. (NYSE: QTS), a leading provider of software-defined and mega-scale data center solutions, announced today that its Board of Directors has authorized a cash dividend of $1.9861111 per share on its 6.50% Series B Cumulative Convertible Perpetual Preferred Stock (the "Series B Convertible Preferred Stock") for the period from and including June 25, 2018 and ending on October 14, 2018. The $1.9861111 per share dividend is payable on October 15, 2018 to holders of Series B Convertible Preferred Stock of record at the close of business on September 30, 2018, which is equivalent to $6.50 per annum per share.
About QTS
QTS Realty Trust, Inc. (NYSE: QTS) is a leading provider of data center solutions across a diverse footprint spanning more than 6 million square feet of owned mega scale data center space throughout North America. Through its software-defined technology platform, QTS is able to deliver secure, compliant infrastructure solutions, robust connectivity and premium customer service to leading hyperscale technology companies, enterprises, and government entities. Visit QTS at www.qtsdatacenters.com, call toll-free 877.QTS.DATA or follow on Twitter @DataCenters_QTS.
Investor Relations Contact:
Stephen Douglas
[email protected]
Media Contact:
Carter B. Cromley
(703) 861-8245
[email protected]
View original content:http://www.prnewswire.com/news-releases/qts-declares-series-b-convertible-preferred-stock-dividend-300695404.html
SOURCE QTS Realty Trust, Inc.
- EQS-News: STEICO SE: Q1 2024 – Stabile Geschäftslage mit positiver Ergebnisentwicklung
- LLB-Generalversammlung 2024 – Aktionäre stimmen allen Anträgen zu
- Clarification of Details Regarding Oceansix's Engagement with RB Milestone Group LLC
- EQS-Adhoc: SYNLAB AG: SYNLAB von Cyber-Angriff in Italien betroffen
- EQS-Adhoc: SynBiotic SE schließt Einbringungsvertrag über den Erwerb aller Anteile an der Ilesol Pharmaceuticals d.o.o. (Kroatien)
- Generalversammlung der Arbonia AG genehmigt alle Anträge